The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions
Open accessAbstract
Chronic active multiple sclerosis lesions, characterized by a hyperintense rim of iron-enriched, activated microglia and macrophages, have been linked to greater tissue damage. Post-mortem studies have determined that chronic active lesions are primarily related to the later stages of multiple sclerosis; however, the occurrence of these lesions, and their relationship to earlier disease stages may be greatly underestimated. Detection of chronic active lesions across the patient spectrum of multiple sclerosis requires a validated imaging tool to accurately identify lesions with persistent inflammation. Quantitative susceptibility mapping provides efficient in vivo quantification of susceptibility changes related to iron deposition and the potential to identify lesions harbouring iron-laden inflammatory cells. The PET tracer 11C-PK11195 targets the translocator protein expressed by activated microglia and infiltrating macrophages. Accordingly, this study aimed to validate that lesions with a hyperintense rim on quantitative susceptibility mapping from both relapsing and progressive patients demonstrate a higher level of innate immune activation as measured on 11C-PK11195 PET. Thirty patients were enrolled in this study, 24 patients had relapsing remitting multiple sclerosis, six had progressive multiple sclerosis, and all patients had concomitant MRI with a gradient echo sequence and PET with 11C-PK11195. A total of 406 chronic lesions were detected, and 43 chronic lesions with a hyperintense rim on quantitative susceptibility mapping were identified as rim+ lesions. Susceptibility (relative to CSF) was higher in rim+ (2.42 ± 17.45 ppb) compared to rim- lesions (-14.6 ± 19.3 ppb, P < 0.0001). Among rim+ lesions, susceptibility within the rim (20.04 ± 14.28 ppb) was significantly higher compared to the core (-5.49 ± 14.44 ppb, P < 0.0001), consistent with the presence of iron. In a mixed-effects model, 11C-PK11195 uptake, representing activated microglia/macrophages, was higher in rim+ lesions compared to rim- lesions (P = 0.015). Validating our in vivo imaging results, multiple sclerosis brain slabs were imaged with quantitative susceptibility mapping and processed for immunohistochemistry. These results showed a positive translocator protein signal throughout the expansive hyperintense border of rim+ lesions, which co-localized with iron containing CD68+ microglia and macrophages. In conclusion, this study provides evidence that suggests that a hyperintense rim on quantitative susceptibility measure within a chronic lesion is a correlate for persistent inflammatory activity and that these lesions can be identified in the relapsing patients. Utilizing quantitative susceptibility measure to differentiate chronic multiple sclerosis lesion subtypes, especially chronic active lesions, would provide a method to assess the impact of these lesions on disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This suggests that the TSPO PET signal arises from astrocytes as well as microglia, which is consistent with reports that newer generation ligands for TSPO bind to reactive astrocytes (Dickens et al., 2014; Kaunzner et al., 2019).”
From A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis (2019) · cites this paper as Kaunzner et al., 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar to a recent study combining quantitative susceptibility mapping and immunohistochemistry (Kaunzner et al., 2019), our studies revealed non-trivial expression of TSPO in astrocytes in all subtypes of lesions examined.”
From A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis (2019) · cites this paper as Kaunzner et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Immunopathology of multiple sclerosis
Dendrou, C. A., Fugger, L., & Friese, M. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3871 · Cited by 2,215
Logan, J., Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., HITZEMANN, R. J., Bendriem, B., Gatley, S. J., et al. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.127 · Cited by 1,481
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155
Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker
Wang, Y., & Liu, T. (2015) · Magnetic Resonance in Medicine · doi:10.1002/mrm.25358 · Cited by 878
Self-citationFrischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., Mandrekar, J., Bramow, S., Metz, I., Brück, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24497 · Cited by 728
de Rochefort, L., Liu, T., Kressler, B., Liu, J., Spincemaille, P., Lebon, V., Wu, J., & Wang, Y. (2009) · Magnetic Resonance in Medicine · doi:10.1002/mrm.22187 · Cited by 672
Self-citationThe peripheral benzodiazepine binding site in the brain in multiple sclerosis
Banati, R. B., Newcombe, J., Gunn, R. N., Cagnin, A., Turkheimer, F., Heppner, F., Price, G., Wegner, F., Giovannoni, G., Miller, D. H., et al. (2000) · Brain · doi:10.1093/brain/123.11.2321 · Cited by 661
Iron and neurodegeneration in the multiple sclerosis brain
Hametner, S., Wimmer, I., Haider, L., Pfeifenbring, S., Brück, W., & Lassmann, H. (2013) · Annals of Neurology · doi:10.1002/ana.23974 · Cited by 519
Quantitative MR Imaging of Brain Iron: A Postmortem Validation Study
Langkammer, C., Krebs, N., Goessler, W., Scheurer, E., Ebner, F., Yen, K., Fazekas, F., & Ropele, S. (2010) · Radiology · doi:10.1148/radiol.10100495 · Cited by 508
Liu, J., Liu, T., de Rochefort, L., Ledoux, J., Khalidov, I., Chen, W., Tsiouris, A. J., Wisnieff, C., Spincemaille, P., Prince, M. R., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.08.082 · Cited by 502
Self-citationSlow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging
Dal-Bianco, A., Grabner, G., Kronnerwetter, C., Weber, M., Höftberger, R., Berger, T., Auff, E., Leutmezer, F., Trattnig, S., Lassmann, H., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1636-z · Cited by 463
Cosenza‐Nashat, M., Zhao, M. ‐., Suh, H. ‐., Morgan, J., Natividad, R., Morgello, S., & Lee, S. C. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.01006.x · Cited by 459
Liu, T., Spincemaille, P., de Rochefort, L., Kressler, B., & Wang, Y. (2009) · Magnetic Resonance in Medicine · doi:10.1002/mrm.21828 · Cited by 454
Self-citationImmunopathology of secondary‐progressive multiple sclerosis
Prineas, J. W., Kwon, E. E., Cho, E., Sharer, L. R., Barnett, M. H., Oleszak, E. L., Hoffman, B. E., & Morgan, B. P. (2001) · Annals of Neurology · doi:10.1002/ana.1255 · Cited by 453
Deistung, A., Schäfer, A., Schweser, F., Biedermann, U., Turner, R., & Reichenbach, J. R. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2012.09.055 · Cited by 442
Visualising microglial activation in vivo
Banati, R. B. (2002) · Glia · doi:10.1002/glia.10144 · Cited by 428
Wilms, H., Sievers, J., Rickert, U., Rostami‐Yazdi, M., Mrowietz, U., & Lucius, R. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-30 · Cited by 355
Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla
Bagnato, F., Hametner, S., Yao, B., van Gelderen, P., Merkle, H., Cantor, F. K., Lassmann, H., & Duyn, J. H. (2011) · Brain · doi:10.1093/brain/awr278 · Cited by 351
Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions
Absinta, M., Sati, P., Schindler, M., Leibovitch, E. C., Ohayon, J., Wu, T., Meani, A., Filippi, M., Jacobson, S., Cortese, I. C. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86198 · Cited by 327
Pathology of multiple sclerosis and related inflammatory demyelinating diseases
Kutzelnigg, A., & Lassmann, H. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52001-2.00002-9 · Cited by 315
Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2
Schulze‐Topphoff, U., Varrin‐Doyer, M., Pekarek, K. L., Spencer, C. M., Shetty, A., Sagan, S. A., Cree, B., Sobel, R. A., Wipke, B. T., Steinman, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603907113 · Cited by 292
Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?
Marik, C., Felts, P. A., Bauer, J., Lassmann, H., & Smith, K. J. (2007) · Brain · doi:10.1093/brain/awm236 · Cited by 292
Hammond, K. E., Metcalf, M., Carvajal, L. E., Okuda, D. T., Srinivasan, R., Vigneron, D. B., Nelson, S. J., & Pelletier, D. (2008) · Annals of Neurology · doi:10.1002/ana.21582 · Cited by 281
Quantitative Susceptibility Mapping in Multiple Sclerosis
Langkammer, C., Liu, T., Khalil, M., Enzinger, C., Jehna, M., Fuchs, S., Fazekas, F., Wang, Y., & Ropele, S. (2013) · Radiology · doi:10.1148/radiol.12120707 · Cited by 281
Self-citationPathology of Multiple Sclerosis: Where Do We Stand?
Popescu, B. F. G., Pirko, I., & Lucchinetti, C. F. (2013) · Continuum · doi:10.1212/01.con.0000433291.23091.65 · Cited by 261
Wisnieff, C., Ramanan, S., Olesik, J., Gauthier, S., Wang, Y., & Pitt, D. (2015) · Magnetic Resonance in Medicine · doi:10.1002/mrm.25420 · Cited by 245
Self-citationQuantitative Susceptibility Mapping of Multiple Sclerosis Lesions at Various Ages
Chen, W., Gauthier, S. A., Gupta, A. K., Comunale, J. P., Liu, T., Wang, S., Pei, M., Pitt, D., & Wang, Y. (2013) · Radiology · doi:10.1148/radiol.13130353 · Cited by 236
Self-citationLiu, Z., Spincemaille, P., Yao, Y., Zhang, Y., & Wang, Y. (2017) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26946 · Cited by 221
Self-citationA basic overview of multiple sclerosis immunopathology
Grigoriadis, N., & Pesch, V. V. (2015) · European Journal of Neurology · doi:10.1111/ene.12798 · Cited by 220
PET visualization of microglia in multiple sclerosis patients using [ 11 C]PK11195
Debruyne, J., Versijpt, J. J., Laere, K. V., Vos, F. D., Keppens, J., Strijckmans, K., Achten, E., Slegers, G., Dierckx, R. A., Korf, J., et al. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00571.x · Cited by 217
Imaging Cortical Lesions in Multiple Sclerosis With Ultra–High-Field Magnetic Resonance Imaging
Pitt, D., Boster, A. L., Pei, W., Wohleb, E., Jasne, A. S., Zachariah, C. R., Rammohan, K. W., Knopp, M. V., & Schmalbrock, P. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.148 · Cited by 210
Self-citationIron Is a Sensitive Biomarker for Inflammation in Multiple Sclerosis Lesions
Mehta, V. B., Pei, W., Yang, G., Li, S., Swamy, E., Boster, A. L., Schmalbrock, P., & Pitt, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057573 · Cited by 209
Self-citationParodi, B., Rossi, S., Morando, S., Cordano, C., Bragoni, A., Motta, C., Usai, C., Wipke, B. T., Scannevin, R. H., Mancardi, G., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1422-3 · Cited by 204
Imaging Microglial Activation with TSPO PET: Lighting Up Neurologic Diseases?
Vivash, L. E., & O'Brien, T. J. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.141713 · Cited by 192
A JAVA environment for medical image data analysis: Initial application for brain PET quantitation
Mikolajczyk, K. P., Szabatin, M., Rudnicki, P., Grodzki, M., & Burger, C. (1998) · Medical Informatics · doi:10.3109/14639239809001400 · Cited by 179
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability
Politis, M., Giannetti, P., Su, P., Turkheimer, F., Keihaninejad, S., Wu, K., Waldman, A., Malik, O., Matthews, P. M., Reynolds, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635645 · Cited by 176
DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner
Gillard, G. O., Collette, B., Anderson, J., Chao, J., Scannevin, R. H., Huss, D. J., & Fontenot, J. D. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.04.006 · Cited by 173
Hammond, K. E., Lupo, J., Xu, D., Metcalf, M., Kelley, D. A. C., Pelletier, D., Chang, S. M., Mukherjee, P., Vigneron, D. B., & Nelson, S. J. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.10.037 · Cited by 166
Absinta, M., Sati, P., Gaitán, M. I., Maggi, P., Cortese, I. C. M., Filippi, M., & Reich, D. S. (2013) · Annals of Neurology · doi:10.1002/ana.23959 · Cited by 165
Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide
Colombo, E., Dario, M. D., Capitolo, E., Chaabane, L., Newcombe, J., Martino, G., & Farina, C. (2014) · Annals of Neurology · doi:10.1002/ana.24217 · Cited by 151
Pathogenic implications of distinct patterns of iron and zinc in chronic MS lesions
Popescu, B. F. G., Frischer, J. M., Webb, S. M., Tham, M., Adiele, R. C., Robinson, C. A., Fitz‐Gibbon, P. D., Weigand, S. D., Metz, I., Nehzati, S., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1696-8 · Cited by 138
18F-GE-180: a novel TSPO radiotracer compared to 11C-R-PK11195 in a preclinical model of stroke
Boutin, H., Murray, K. N., Pradillo, J. M., Maroy, R., Smigova, A., Gerhard, A., Jones, P. A., & Trigg, W. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2939-8 · Cited by 125
The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures
O’Sullivan, C., Schubart, A., Mir, A. K., & Dev, K. K. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0494-x · Cited by 124
Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS
Hammoud, D. A., Endres, C. J., Chander, A., Guilarte, T. R., Wong, D. F., Sacktor, N. C., McArthur, J. C., & Pomper, M. G. (2005) · Journal of NeuroVirology · doi:10.1080/13550280500187351 · Cited by 115
Deh, K., Nguyen, T. D., Eskreis‐Winkler, S., Prince, M. R., Spincemaille, P., Gauthier, S. A., Kovanlıkaya, İ., Zhang, Y., & Wang, Y. (2015) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24943 · Cited by 111
Self-citationIncreased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome
Giannetti, P., Politis, M., Su, P., Turkheimer, F., Malik, O., Shiva Keihaninejad, A., Wu, K., Waldman, A. D., Reynolds, R., Nicholas, R. S., et al. (2014) · Brain · doi:10.1093/brain/awu331 · Cited by 106
Jučaitė, A., Cselényi, Z., Arvidsson, A., Åhlberg, G., Julin, P., Varnäs, K., Stenkrona, P., Andersson, J. D., Halldin, C., & Farde, L. (2012) · EJNMMI Research · doi:10.1186/2191-219x-2-15 · Cited by 101
Sucksdorff, M., Rissanen, E., Tuisku, J., Nuutinen, S., Paavilainen, T., Rokka, J., Rinne, J. O., & Airas, L. M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183020 · Cited by 95
Draheim, T., Liessem, A., Scheld, M., Wilms, F., Weißflog, M., Denecke, B., Kensler, T. W., Zendedel, A., Beyer, C., Kipp, M., et al. (2016) · Glia · doi:10.1002/glia.23058 · Cited by 95
Zhang, Y., Gauthier, S. A., Gupta, A. K., Comunale, J. P., Chiang, G. C.-Y., Zhou, D., Chen, W., Giambrone, A. E., Zhu, W., & Wang, Y. (2016) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25144 · Cited by 92
Self-citationDecreased microglial activation in MS patients treated with glatiramer acetate
Ratchford, J. N., Endres, C. J., Hammoud, D. A., Pomper, M. G., Shiee, N., McGready, J., Pham, D. L., & Calabresi, P. A. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6337-x · Cited by 91
Lesion Heterogeneity on High-Field Susceptibility MRI Is Associated with Multiple Sclerosis Severity
Harrison, D. M., Li, X., Liu, H., Jones, C. K., Caffo, B. S., Calabresi, P. A., & van Zijl, P. C. M. (2016) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4726 · Cited by 89
Cytokine toxicity to oligodendrocyte precursors is mediated by iron
Zhang, X., Haaf, M., Todorich, B., Grosstephan, E., Schieremberg, H., Surguladze, N., & Connor, J. R. (2005) · Glia · doi:10.1002/glia.20235 · Cited by 87
Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis
Diebold, M., Sievers, C., Bantug, G. R., Sanderson, N., Kappos, L., Kühle, J., Lindberg, R. L. P., & Derfuss, T. J. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.09.009 · Cited by 77
Peng, H., Li, H., Sheehy, A. M., Cullen, P. F., Allaire, N., & Scannevin, R. H. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.08.006 · Cited by 57
Yao, Y., Nguyen, T. D., Pandya, S., Zhang, Y., Rúa, S. H., Kovanlıkaya, İ., Kuceyeski, A. F., Liu, Z., Wang, Y., & Gauthier, S. A. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5482 · Cited by 56
Self-citationGoyal, K., Koul, V., Singh, Y., & Anand, A. (2014) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524914666141030145948 · Cited by 49
Roivainen, A., Någren, K., Hirvonen, J., Oikonen, V., Virsu, P., Tolvanen, T., & Rinne, J. O. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-1000-1 · Cited by 42
Yao, B., Ikonomidou, V. N., Cantor, F. K., Ohayon, J. M., Duyn, J. H., & Bagnato, F. R. (2015) · Journal of Neuroimaging · doi:10.1111/jon.12193 · Cited by 40
Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation
Kaunzner, U. W., Kang, Y., Monohan, E., Kothari, P. J., Nealon, N., Perumal, J. S., Vartanian, T. K., Kuceyeski, A. F., Vallabhajosula, S., Mozley, P. D., et al. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.04.008 · Cited by 39
Self-citationFaissner, S., Mahjoub, Y., Mishra, M. K., Haupeltshofer, S., Hahn, J. N., Gold, R., Koch, M. W., Metz, L. M., Ben‐Hur, T., & Yong, V. W. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517728811 · Cited by 37
Demyelination induced by oxidative stress is regulated by sphingosine 1‐phosphate receptors
O’Sullivan, S. A., Velasco‐Estevez, M., & Dev, K. K. (2017) · Glia · doi:10.1002/glia.23148 · Cited by 36
Cited by
Sorted by citations
Multiple sclerosis progression: time for a new mechanism-driven framework
Kuhlmann, T., Moccia, M., Coetzee, T., Cohen, J. A., Correale, J., Graves, J., Marrie, R. A., Montalban, X., Yong, V. W., Thompson, A. J., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00289-7 · Cited by 667
Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo
Absinta, M., Sati, P., Masuzzo, F., Nair, G., Sethi, V., Kolb, H., Ohayon, J., Wu, T., Cortese, I. C. M., & Reich, D. S. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2399 · Cited by 534
Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI
Dal‐Bianco, A., Grabner, G., Kronnerwetter, C., Weber, M., Kornek, B., Kasprian, G. J., Berger, T., Leutmezer, F., Rommer, P. S., Trattnig, S., et al. (2020) · Brain · doi:10.1093/brain/awaa436 · Cited by 230
Microglia in multiple sclerosis: Friend or foe
Guerrero, B. L., & Sicotte, N. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00374 · Cited by 215
Imaging chronic active lesions in multiple sclerosis: a consensus statement
Bagnato, F. R., Sati, P., Hemond, C. C., Elliott, C., Gauthier, S. A., Harrison, D. M., Mainero, C., Oh, J., Pitt, D., Shinohara, R. T., et al. (2024) · Brain · doi:10.1093/brain/awae013 · Cited by 207
Self-citation
Metadata
- Authors
- Kaunzner, U. W., Kang, Y., Zhang, S., Morris, E., Yao, Y., Pandya, S., Hurtado Rua, S. M., Park, C., Gillen, K. M., Nguyen, T. D., Wang, Y., Pitt, D., & Gauthier, S. A.
- Affiliations
- Weill Cornell Medicine (US)
- Cornell MRI Research Lab, New York City, NY, USA
- Department of Mathematics, College of Sciences and Health Professions, Cleveland State University, Cleveland, OH, USA
- Yale University (US)
- Corresponding author
- Gauthier, Susan A
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-12-15
- Volume
- 142
- Issue
- 1
- Pages
- 133-145
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6308309
- OpenAlex
- W2904004727
- Cited by
- 199
- References
- 63
- Citations by year
- 2026: 15 · 2025: 20 · 2024: 40 · 2023: 27 · 2022: 33 · 2021: 30 · 2020: 23 · 2019: 11
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- EngagedScholarship @ Cleveland State University (Cleveland State University) (submittedVersion)
- Funders
- National Institutes of Health (RO1 NS090464)
- Biogen (55000025)
- Genzyme (56585757)
- Novartis (56585786, UL1 TR000456-06)
- Weill Cornell Clinical and Translational Science Center
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- chronic active lesions, quantitative susceptibility mapping, [11C]PK11195, translocator protein (TSPO), microglial activation, macrophages, iron accumulation, innate immune activation, relapsing-remitting multiple sclerosis, progressive multiple sclerosis, CD68, immunohistochemistry
- MeSH terms
- CD68 Molecule, Adult, Aged, Brain, Carbon Radioisotopes, Chronic Disease, Cross-Sectional Studies, Female, Humans, Inflammation, Iron, Isoquinolines, Macrophages, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Retrospective Studies, Antigens, Differentiation, Myelomonocytic, Antigens, CD, Microglia, Positron-Emission Tomography, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
